Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: trastuzumab|DRUG: pyrotinib|DRUG: fulvestrant
Sponsor: Fudan University